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Objectives: Our primary aim was to study diabetes mellitus (DM) arising during combination ART (cART) and to
attempt to identify associations between these cases and triglycerides (TRG) and the TRG to HDL-cholesterol
(TRG/HDL) ratio. Our secondary aim was to analyse the association between DM development and hepatic fibrosis.
Methods: This was a retrospective cohort study. Patients from the Icona Foundation study initiating first-line cART
between 1997 and 2013 were selected and observed until new-onset DM or most recent clinical follow-up. The pre-
dictive value of TRG and TRG/HDL ratio levels on DM was evaluated using multivariable Poisson regression models.
Results: Three-thousand, five-hundred and forty-six patients (males, 73.7%; median age, 38 years; median BMI,
23.1 kg/m2; and hepatitis C virus antibody positive, 22.1%) were included. Of these, 80 developed DM over 13911
person-years of follow-up (PYFU), corresponding to 5.7 cases per 1000 PYFU (95% CI¼4.6–7.1). At multivariable
analysis, latest TRG/HDL ratio, when high, was associated with significant increases in DM risk [relative risk
(RR)¼1.63; 95% CI¼1.32–2.01 per 10 points higher], while current TRG, in contrast, was associated with
new-onset DM only at crude analysis. Advanced liver fibrosis (defined as fibrosis-4 index .3.25) was also
shown to be an independent risk factor for DM (RR¼2.91; 95% CI¼1.10–7.72).
Conclusions: High TRG/HDL ratio predicted risk of new-onset DM, independently of other traditional risk factors.
Furthermore, our findings suggest that advanced hepatic fibrosis, estimated using the fibrosis-4 score, could pro-
vide an additional predictor for DM.
Introduction
Combination ART (cART) has dramatically reduced morbidity and
mortality in HIV-infected patients, prolonging their life expect-
ancy.1 At the same time, ageing and related comorbidities re-
present serious challenges in this population. The incidence of
comorbidities associated with ageing appears to be much higher
and to occur earlier in HIV-infected individuals with respect to
their HIV-uninfected counterparts.2
Increased risk of diabetes mellitus (DM) in HIV-infected subjects is
a matter of debate. Whilst an association between HIV infection and
heightened risk of diabetes has been demonstrated in some stud-
ies,3–5 other researchers have failed to support such findings.6–8
Dyslipidaemia is a common feature among HIV-infected patients,
particularly during cART. According to the American Diabetes
Association, all overweight patients whose HDL-cholesterol
(HDL-c) values are ,35 mg/dL (0.9 mmol/L) and whose triglycer-
ide (TRG) values are .250 mg/dL (2.8 mmol/L) should undergo
testing for diabetes.9 Moreover, the ratio between TRG and HDL-c
levels (TRG/HDL) has been cited as a marker of insulin resistance,
which is the most important risk factor for developing DM.10–12
Although high TRG and low HDL-c are frequently found in
HIV-infected patients on cART,13 they are not always associated
with obesity. This is because HIV-infected patients often have
lower BMIs compared with the general population.14 In addition,
the relationship between HDL-c and TRG plasma levels has been
postulated to be different in patients with HIV-related, with
respect to non-HIV-related, dyslipidaemia.15 Finally, cART intro-
duction heavily alters the lipid profile within the HIV-infected
population.16
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Hence, the predictive roles of TRG, HDL-c and TRG/HDL in the
development of DM are not well established in HIV-infected patients,
since it is unclear whether abnormalities in these levels are asso-
ciated with DM or are merely side effects of cART that have little
impact on DM onset. This question merits further evaluation.
Our primary aim was to verify the association between TRG and
TRG/HDL ratio and diabetes onset. Our secondary objective was to
evaluate associations between DM and liver fibrosis during cART,
given the known association between insulin resistance and non-
alcoholic fatty liver disease (NAFLD).17,18
Methods
The Icona Foundation Study is a cohort of HIV-infected patients, which
superseded the original Italian Cohort of Antiretroviral-Naive Patients
study (detailed description of this cohort elsewhere),19 recruiting
HIV-positive naive patients. CD4+ cell counts and viral load are measured
at least every 6 months, as are other laboratory parameters as well as
clinical and therapeutical data.
Ethics
All patients signed consent forms to participate in the Icona Foundation
Study, in accordance with the ethics standards of the committee on
human experimentation and the Helsinki Declaration (1983 revision).
Inclusion/exclusion criteria
Patients enrolled in the Icona Foundation cohort were included in the pre-
sent analysis if: (i) they had begun cART while naive to antiretrovirals, from
1 January 1997 or later; (ii) they had at least one TRG and HDL-c fasting
value before baseline, which was defined as cART initiation; (iii) they had
a baseline fasting blood glucose ≤126 mg/dL (7 mmol/L); (iv) they were
never exposed to antidiabetic or lipid-lowering drugs before baseline;
and (v) they had no diagnosis of DM prior to cART initiation.
Definitions
DM was defined as two consecutive blood glucose values of .126 mg/dL
(7 mmol/L), clinical diagnosis of DM or start of antidiabetes treatment.
Incidence rate of DM was calculated as the number of observed cases of
DM subsequent to cART initiation divided by person-years of follow-up
(PYFU). The follow-up (FU) period began at commencement of cART and
lasted until onset of DM, death or lost to FU, whichever occurred first.
Liver fibrosis was evaluated using the fibrosis-4 (FIB-4) score, calcu-
lated as: (age×AST)/[platelets×square root (ALT)], and divided into three
categories as follows:20,21 (i) FIB-4 value .3.25 as a proxy for advanced
fibrosis; (ii) FIB-4 value between 1.45 and 3.25 for which fibrosis status
is considered to be undetermined; and (iii) FIB-4 value ,1.45 considered
to be absence of advanced fibrosis.
Statistical analysis
Univariable and multivariable Poisson regression models were fitted to
assess factors associated with post-cART DM development. Crude relative
risks (RRs) were estimated for the following: (i) fixed covariates (gender,
mode of HIV infection, nationality, years of infection and nadir
CD4 cell/mm3); (ii) covariates at cART start [age, CDC stage, CD4 and
log10 HIV-RNA, hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfec-
tion, total cholesterol and TRG and TRG/HDL]; and (iii) time-dependent cov-
ariates that could change value over the course of the observation period
and that included all consecutive values of each single variable during the
FU and that were called FU variables in the text (BMI, total cholesterol, TRG,
TRG/HDL, type of antiretroviral regimen, type of backbone combination
and type of third drug in the regimen, alcohol use and FIB-4).
Patients were pooled according to TRG values at baseline and during
FU: (i) ≤180 mg/dL (normal TRG); (ii) 181–300 mg/dL (mild hypertriglycer-
idaemia); and (iii) .300 mg/dL (moderate/severe hypertriglyceridaemia).
Two different multivariable Poisson regression models were fitted,
including all factors associated with P values of ,0.2 at univariable ana-
lysis. An initial model included time-updated values of TRG/HDL
expressed as FU-TRG/HDL (model A) and a second model included time-
updated values of TRG expressed as FU-TRG (model B).
Results
Of the 3546 patients included in our analysis, 80 developed DM
over 13911 PYFU, representing an incidence rate of 5.7 per 1000
PYFU (95% CI¼4.6–7.1). Most patients were males (73.7%) and
their median age was 38 years (IQR¼33–45). The median BMI
at baseline was 23.1 kg/m2 (IQR¼21.1 –25.2) and 22.1% of
patients tested positive for HCV antibodies (HCV-Ab). At baseline,
most patients (82.6%) had normal TRG levels, normal HDL (73%
of sample) and the median TRG/HDL ratio was 2.8 (IQR¼1.8–4.5).
Complete patient characteristics are given in Table 1.
During FU, 28562 TRG/HDL values were calculated. FU-TRG/HDL
ratios affected the DM incidence rate: 1.8/1000 PYFU (95%
CI¼0.8–4.0) for subjects with ratios lower than the first quartile
(TRG/HDL ratio 0–1.69); 3.9/1000 PYFU (95% CI¼2.2–6.8) for ratios
between the first and second quartiles (TRG/HDL ratio 1.7–2.69);
5.6/1000 PYFU (95% CI¼3.5–9.0) for ratios between the second
and third quartiles (TRG/HDL ratio 2.7–4.5); and 9.8/1000 PYFU
(95% CI¼6.8–14.0) for ratios above the third quartile (TRG/HDL
ratio .4.5) (Figure 1).
FU-FIB-4 score was also associated with increased DM inci-
dence: 3.7/1000 PYFU (95% CI¼2.7–5.0) for subjects with FIB-4
scores of ,1.5; 11.4/1000 PYFU (95% CI¼7.5–17.4) for scores
between 1.5 and 3.25; and 16.8/1000 PYFU (95% CI¼8.4–33.6)
for FIB-4 scores of .3.25.
At univariable analysis, abnormal values (181 –300 and
.300 mg/dL) of basal TRG as well as time-updated values
(FU-TRG) were significantly associated with a higher risk of dia-
betes onset compared with normal values (≤180 mg/dL).
Patients with mild (TRG between 181 and 300 mg/dL) and mod-
erate/severe hypertriglyceridaemia (TRG .300 mg/dL) at baseline
had RR¼4.16 (95% CI¼2.62–6.62; P,0.001) and RR¼2.78 (95%
CI¼1.18–6.52; P¼0.019), respectively, versus patients with nor-
mal values.
Similarly, patients with FU-TRG in the mild and moderate/severe
groups were at higher risk of DM [RR¼1.83 (95% CI¼1.07–3.13;
P,0.05) and RR¼3.55 (95% CI¼2.01–6.28; P,0.001), respect-
ively] compared with subjects with normal values.
Additionally, higher TRG/HDL ratio values, both at baseline
and during FU, were associated with a higher risk of new dia-
betes diagnosis, with RR¼1.16 per 10 points higher (95%
CI¼1.06–1.27; P¼0.001) and RR¼1.18 (95% CI¼1.10 –1.26;
P,0.001), respectively.
At univariable analysis, the following risk factors were found to
be associated with higher risk of DM: higher age; male gender;
nadir CD4 ,200 cells/mm3; CDC C stage versus stage A/B;
HCV-Ab positive versus negative; baseline cholesterol between
201 and 239 mg/dL versus normal value ≤200 mg/dL; FU-BMI
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FU-BMI ,25 kg/m2; use of stavudine plus lamivudine in the cur-
rent regimen versus tenofovir plus emtricitabine, use of indinavir+
ritonavir in the current regimen versus efavirenz; and FU-FIB-4
score between 1.5 and 3.25 or .3.25 versus ,1.5. Full results
are shown in Table 2.
Multivariable analysis (models A and B) is shown in Table 2. The
two models differed by the way FU-TRG was modelled: model A
included the FU-TRG/HDL ratio, while model B included FU-TRG.
In model A, higher FU-TRG/HDL ratio was associated with higher
risk of DM, independently of all factors included and of FU-FIB-4
value. Other factors independently associated with higher risk of
diabetes onset were: older age (per 10 year older, RR¼1.44; 95%
CI¼1.06 –1.95; P,0.05); FU-BMI .30 kg/m2 (4.92; 95%
CI¼2.42 –10.00 versus BMI ,25 kg/m2; P,0.001); use of
stavudine+ lamivudine in FU regimens (6.31; 95% CI¼1.95–20.40
versus tenofovir+emtricitabine; P,0.01); use of atazanavir/
ritonavir (3.23; 95% CI¼1.30–7.98 versus efavirenz; P,0.05); higher
FU-TRG/HDL ratios (per 10 points higher 1.63; 95% CI¼1.32–2.01;
P,0.001); baseline cholesterol between 201 and 239 mg/dL (2.49;
95% CI¼1.30–4.78 versus ≤200 mg/dL; P,0.05); and FU-FIB-4
.3.25 (2.91; 95% CI¼1.10–7.72 versus ,1.5; P,0.05).
Additionally, advanced liver fibrosis (defined as FIB-4 index
.3.25) was independently associated with higher risk of DM, par-
ticularly in model A, with only marginal association evident in
model B (Table 2). Of note, this association was much stronger
among patients without HCV coinfection (RR¼5.28; 95%
CI¼1.25–22.27) than in those with positive HCV-Ab (RR¼1.91;
95% CI¼0.61–6.0; P value for interaction¼0.02). In a multivari-
ate model excluding FIB-4, HCV-Ab positivity was independently
associated with DM development, confirming a strong interaction
between FIB-4 and HCV (data not shown).
We also explored the risk of diabetes when high values of
TRG/HDL and FIB-4 were coexisting and found that in patients
with a TRG/HDL ≥4.5 (III quartile) and a FIB-4 .3.25, the RR of
diabetes was 4.03 versus those with TRG/HDL ,4.5 and FIB-4
,1.5 (95% CI¼0.86–19.03; P¼0.08), confirming a cumulative
effect of the two different markers even if this does not reach stat-
istical significance. The interaction test between TRG/HDL and
FIB-4 score was not significant (P¼0.33).
Discussion
Our primary goal was to evaluate the incidence and determinants
of diabetes in a large cohort of previously ART-naive patients
initiating cART in Italy. In this cohort, incidence of new-onset dia-
betes was as high as 5.7 per 1000 PYFU, not significantly higher
than the incidence reported for uninfected subjects in Italy.22,23
Comparing our data with those obtained from other large cohorts
of HIV-infected subjects, we found that our findings were very
similar to incidences found in the DAD8 and Swiss HIV cohorts,6
but lower than that reported from the ANRS study.5 The discrep-
ancy between our findings and those of the French study may be
attributable to several factors. There were significant age disparities
between the two populations: nearly 70% of patients in the
French study were .40 years of age, while the median age in
our population was 38 years. Also, in our analysis only 37% had
started cART before 2005, while the French cohort included
patients initiating cART between 1997 and 1999. Such differences
Table 1. Study population characteristics, N¼3546
Male, n (%) 2612 (73.7)
Age (years), median (IQR) 38 (33–45)
Mode of HIV transmission, n (%)




Italian nationality, n (%) 3045 (85.9)
Duration of HIV infection (years), median (IQR) 1.5 (0.2–5.6)
CDC stage C, n (%) 355 (10.0)
Nadir CD4 cells/mm3, median (IQR) 270 (170–361)
,200 cells/mm3, n (%) 1051 (29.6)
Baseline CD4 cells/mm3, median (IQR) 286 (181–384)
Baseline log10 HIV-RNA (copies/mL), median (IQR) 4.8 (4.2–5.2)
HCV positivity, n (%) 766 (22.1)
HBV positivity, n (%) 159 (4.5)
Baseline BMI, n (%)
,25 kg/m2 1875 (52.9)
25–29.99 kg/m2 588 (16.6)
≥30 kg/m2 131 (3.7)
unknown 952 (26.8)
Baseline total cholesterol, n (%)
≤200 mg/dL 2943 (83.0)
201–239 mg/dL 423 (11.9)
≥240 mg/dL 104 (2.9)
unknown 76 (2.1)
Baseline HDL-c ,35 mg/dL, n (%) 957 (27.0)
Baseline TRG, n (%)
≤180 mg/dL 2929 (82.6)
181–300 mg/dL 489 (13.8)
.300 mg/dL 128 (3.6)
Baseline TRG/HDL ratio, median (IQR) 2.79 (1.76–4.53)
Baseline FIB-4 score, median (IQR) 0.87 (0.62–1.28)




only NRTIs 137 (3.9)
other 127 (3.6)













/jac/article/71/9/2663/2238396 by guest on 30 O
ctober 2020
in calendar year of inclusion could be an important variable, trans-
lating into exposure to different antiretroviral regimens. For
example, in the French study, new-onset diabetes peaked in
1999–2000 and the subsequent marked decrease is likely to be
related to exposure to first-generation antiretrovirals.
In our study, we did not have a control group of HIV-negative
subjects; however, the incidence of diabetes we observed in this
large cohort of HIV-infected patients was similar to the incidence
reported in a sample of HIV-negative subjects of the same age in
northern Italy (5.7 versus 5.8 per 1000 PYFU).22 Studies conducted
in the USA produced conflicting results when comparing HIV-
infected patients with HIV-uninfected controls. In the Multicentre
AIDS Cohort Study, Brown et al.4 reported a significantly higher inci-
dence of diabetes in HIV-infected males on cART compared with
HIV-negative males. In contrast, the incidence of diabetes in
HIV-infected women in the Women’s Interagency Study, under-
taken by Tien et al.,7 was significantly lower than that of the
Multicentre AIDS Cohort Study, with no observable differences
seen between HIV-infected and -uninfected women. It should be
noted, however, that each of these studies used a different definition
for diabetes; only the study of Tien et al.,7 as ours, used the American
Diabetes Association guidelines criteria for definition of DM.
Aiming to define independent predictors of new-onset dia-
betes, we have found that TRG levels and TRG/HDL ratios in our
cohort are predictive of subsequent diabetes in patients initiating
cART. This is consistent with data obtained in the general popula-
tion for overweight individuals,24 since high prevalence of insulin
resistance in subjects with BMI .25 kg/m2 usually determines
increases in TRG levels and a proportional decrease in HDL.25
Importantly, in our study, more than half of patients had a nor-
mal BMI, allowing us to confirm the usefulness of the TRG/HDL
ratio in predicting diabetes, even in non-overweight HIV-infected
patients.
One explanation for the association between TRG/HDL ratio and
development of diabetes in HIV-infected patients could be that dys-
lipidaemia and/or insulin resistance are involved in the pathogen-
esis of type 2 diabetes, paralleling data obtained in the general
population.23,26 Indeed, several reports have suggested that dyslipi-
daemia, in particular high TRG and low HDL levels, play a role in the
development of diabetes in HIV-negative patients.27–29Lipotoxicity,
inflammation and endoplasmic reticulum stress are the three
pathogenetic mechanisms that have been postulated to explain
this association30 – 32 and maintaining healthy HDL-c levels
has recently been proposed as a means of preventing diabetes.33
In HIV-positive patients, the relation between HIV replication,
chronic subclinical inflammation and use of cART may enhance
the link between dyslipidaemia and diabetes and thus needs to
be investigated. Vu et al.15 recently demonstrated that the inverse
correlation between TRG and HDL-c found in the general popula-
tion is not present in the HIV population. In determining these
results, the authors took into account the CD4 count and detect-
able viral load, both of which are possible factors affecting the cor-
relation between HDL-c and TRG. Moreover, the authors showed
that HIV patients possess a unique cholesteryl ester transfer
protein mass, as well as specific activity. With these factors in
mind, our study may prove to be a useful tool in confirming an
association—already well defined in general population—that
merits further investigation in HIV-infected patients on cART,
due to the unique characteristics of this population.
The introduction of cART determines an increase in all the lipid
profile setting values.16 The role of cART in the development of
dyslipidaemia is therefore of great significance. For these reasons,
≤180 181–300 >300 min-I q I-II q II-III q <1.5 1.5–3.25 >3.25III q-max
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Table 2. Univariate and multivariate models
Univariable Multivariable—model A Multivariable—model B
RR 95% CI P ARR 95% CI P ARR 95% CI P
Male versus female 2.42 1.31–4.47 0.005 2.09 0.91–4.79 0.083 1.71 0.85–3.46 0.136
Age (per 10 years older) 1.89 1.55–2.30 ,0.001 1.44 1.06–1.95 0.019 1.64 1.26–2.13 0.000
Italian versus not Italian 2.00 0.73–5.47 0.176 1.10 0.29–4.26 0.887 0.69 0.24–1.99 0.488
Nadir CD4 ,200 cells/mm3 2.06 1.31–3.21 0.002 1.16 0.87–1.54 0.320 1.14 0.89–1.47 0.304
CDC stage C versus A/B 2.23 1.32–3.77 0.003 1.18 0.54–2.59 0.676 1.40 0.73–2.70 0.315
HIV-RNA at baseline (log10 copies/mL)
(per 1 log higher)
1.22 0.92–1.63 0.173 1.09 0.79–1.52 0.599 1.10 0.82–1.48 0.527
HCV-Ab positive versus negative 1.62 1.01–2.60 0.047 1.70 0.88–3.25 0.112 1.90 1.07–3.36 0.028
Baseline cholesterol (mg/dL)
≤200 1.00 1.00 1.00
201–239 1.98 1.15–3.41 0.014 2.49 1.30–4.78 0.006 1.82 0.99–3.35 0.054
≥240 1.01 0.25–4.15 0.988 0.80 0.11–5.98 0.832 1.09 0.26–4.58 0.909
FU-TRG/HDL (per 10 points higher) 1.18 1.10–1.26 ,0.001 1.63 1.32–2.01 ,0.001
FU-TRG (mg/dL)
≤180 1.00 1.00
181–300 1.83 1.07–3.13 0.027 1.67 0.93–2.98 0.086
.300 3.55 2.01–6.28 ,0.001 2.35 1.19–4.66 0.014
FU-BMI (kg/m2)
,25 1.00 1.00 1.00
25–29.99 2.36 1.38–4.02 0.002 1.64 0.87–3.10 0.126 1.99 1.13–3.51 0.017
≥30 6.76 3.78–12.10 ,0.001 4.92 2.42–10.00 ,0.001 5.51 2.83–10.71 ,0.001
FU-FIB-4 score
,1.5 1.00 1.00 1.00
1.5–3.25 3.12 1.84–5.27 ,0.001 1.97 1.01–3.87 0.048 1.72 0.92–3.19 0.088
.3.25 4.58 2.14–9.81 ,0.001 2.91 1.10–7.72 0.031 2.38 0.92–6.19 0.074
NRTIs in the current regimen
tenofovir+emtricitabine 1.00 1.00 1.00
tenofovir+ lamivudine 0.92 0.28–3.07 0.896 1.37 0.37–5.07 0.639 1.32 0.36–4.81 0.679
abacavir+ lamivudine 1.10 0.42–2.89 0.847 1.13 0.32–3.98 0.850 1.43 0.47–4.38 0.529
zidovudine+ lamivudine 1.39 0.77–2.54 0.277 2.16 0.84–5.54 0.110 1.83 0.75–4.49 0.184
stavudine+ lamivudine 3.92 1.82–8.48 0.001 6.31 1.95–20.40 0.002 4.48 1.52–13.24 0.007
didanosine+ lamivudine 2.55 0.88–7.37 0.084 2.09 0.44–9.90 0.352 2.74 0.74–10.21 0.132
other 1.99 1.05–3.77 0.034 2.38 0.65–8.63 0.189 3.29 1.09–9.95 0.035
Third drug in the current regimen
efavirenz 1.00 1.00 1.00
nevirapine 0.93 0.39–2.19 0.863 1.19 0.42–3.33 0.745 0.87 0.33–2.34 0.790
lopinavir/ritonavir 1.81 0.92–3.59 0.087 1.20 0.47–3.10 0.702 1.12 0.48–2.65 0.788
atazanavir/ritonavir 1.55 0.74–3.24 0.240 3.23 1.30–7.98 0.011 2.40 1.03–5.63 0.043
fosamprenavir/ritonavir 0.87 0.12–6.47 0.890 1.53 0.19–12.40 0.692 1.35 0.17–10.69 0.776
indinavir+ritonavir 3.13 1.26–7.79 0.014 1.25 0.26–6.16 0.780 1.54 0.54–4.44 0.422
saquinavir+ritonavir 3.23 0.76–13.83 0.114 — — 0.999 3.55 0.76–16.62 0.108
nelfinavir 1.35 0.40–4.55 0.626 1.59 0.34–7.37 0.557 1.56 0.43–5.64 0.497
only NRTI 1.73 0.79–3.81 0.171 1.51 0.39–5.86 0.552 0.90 0.28–2.89 0.857
other 0.97 0.41–2.29 0.943 0.95 0.29–3.15 0.931 0.72 0.24–2.19 0.567
Calendar year of cART start (per 1 year more) 0.95 0.90–1.01 0.099 1.02 0.92–1.14 0.689 1.00 0.91–1.10 0.956
RR, relative risk; ARR, adjusted relative risk.
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and because of the low BMI seen in the majority of HIV-positive
patients with or without lipoatrophy,14 our finding that the TRG/
HDL ratio is predictive of DM, independently of BMI, is of great sig-
nificance and justifies screening for diabetes in HIV-infected
patients with high TRG and TRG/HDL ratio.
Another important concern highlighted by our findings is the
optimal cut-off for the TRG/HDL ratio in HIV-infected patients. A
significant cut-off of TRG/HDL has been proposed in the general
population (.3), which has been demonstrated to be effective
in overweight subjects.24 In our study, we found a significantly
higher incidence of new-onset diabetes for patients in the third
quartile for TRG/HDL ratio, corresponding to a ratio value of .4.5
with a sensitivity of 45.3% and a specificity of 75%. Considering a
cut-off of 3.5, sensitivity was higher (62.5%) and specificity was
reduced (64.1%) (data not shown). Therefore, we could argue
that a cut-off of 4.5 should be used for the HIV population, espe-
cially in patients with a normal BMI.
The relation between type of cART, dyslipidaemia and inci-
dence of diabetes is a major issue for the management of HIV
patients. We found a strong association between new-onset DM
and exposure to cART, especially with stavudine and indinavir
use, consistent with the proven ability of these drugs to induce
insulin resistance.5,6 The association we found with atazanavir is
difficult to explain. It did not change even after correcting for ata-
zanavir in the first regimen or as a switch. It may reflect the PI
class effect and the wide use of atazanavir in recent years, espe-
cially among patients with metabolic complications.
Our study also explored the predictive value of a liver fibrosis
marker (FIB-4) in detecting patients at risk of DM. In the general
population, advanced liver fibrosis (defined as FIB-4 index .3.25)
has been associated with diabetes, due to the high prevalence of
NAFLD in diabetic patients and drug-induced steatosis.17,18 FIB-4
has therefore been proposed as an indirect marker correlating
with progressive metabolic alterations.
In our cohort, a FIB-4 value of .3.25 was significantly asso-
ciated with new-onset DM in HCV-Ab-negative subjects; further-
more, a strong interaction was found between FIB-4 and HCV,
as expected. Hepatic fibrosis could be a marker of increased risk
of diabetes both for metabolic steatosis and for viral steatosis
due to HCV. The association between HCV and diabetes is well
described in literature.34,35 Together with the TRG/HDL ratio,
FIB-4 .3.25 could therefore prove to be a useful tool for identify-
ing patients with hepatic damage caused both by metabolic and
HCV-induced steatosis.
Our study has some limitations. We did not collect waist circum-
ference, which could allow us to evaluate the prevalence of meta-
bolic syndrome in our cohort. Waist circumference is a valid marker
of diabetes risk and could add important information to our results.
On the other hand we focused our attention on a surrogate marker
of insulin resistance (TRG/HDL ratio) that is considered the driving
force of metabolic syndrome components. Another limit was the
lack of data regarding HCV-RNA replication in patients with
HCV-Ab positivity that should have provided the exact impact of
HCV-related damage. However, we did not consider HCV role in
our conclusions because of this limit. Our analysis is based on an
observational study and does not have the strength to define a
real causality between the risk factors and development of dia-
betes, especially regarding the associations with ART regimens.
In conclusion, in studying a cohort of HIV-infected patients
previously naive to cART, we found that incidence of diabetes
was more frequent in subjects with lipid abnormalities, with or
without high BMI. The TRG/HDL ratio proved to be an independent
predictor of diabetes and thus a simple and useful marker to iden-
tify patients with insulin resistance who are at subsequent risk of
diabetes, in order to enact early prevention strategies. High TRG
levels observed during cART are likely to be not only a conse-
quence of therapy, but an effective marker of insulin resistance,
even in the presence of normal BMI. Moreover, measurement of
liver fibrosis by FIB-4 could be of use as a supplemental DM surro-
gate marker.
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